scout
|Videos|July 11, 2017

Phase III Findings for Lenvatinib in HCC

Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME